Table 2.
Number of events, person-time, and incidence rates for cardiovascular effectiveness outcomes in 1:1 PS-matched initiators of SGLT2i versus GLP-1RA
| SGLT2i (N = 45,047) | GLP-1RA (N = 45,047) | SGLT2i vs. GLP-1RA | ||
|---|---|---|---|---|
| HR (95% CI) | RD/1,000 PY (95% CI) | |||
| Primary outcomes | ||||
| MACE∗ | 597 (17.99) | 553 (18.37) | 0.98 (0.87, 1.10) | −0.38 (−2.48, 1.72) |
| HHF | 234 (7.02) | 309 (10.25) | 0.68 (0.57, 0.80) | −3.23 (−4.68, −1.77) |
| Secondary effectiveness outcomes | ||||
| MI | 301 (9.05) | 277 (9.18) | 0.98 (0.84, 1.16) | −0.14 (−1.63, 1.35) |
| Ischemic or hemorrhagic stroke | 214 (6.43) | 187 (6.19) | 1.04 (0.86, 1.27) | 0.24 (−1.00, 1.47) |
| Cardiovascular mortality | 115 (3.44) | 124 (4.10) | 0.83 (0.64, 1.07) | −0.65 (−1.61, 0.30) |
| All-cause mortality | 310 (9.28) | 293 (9.68) | 0.95 (0.81, 1.11) | −0.40 (−1.91, 1.12) |
| MACE or HHF† | 803 (24.24) | 820 (27.33) | 0.89 (0.80, 0.98) | −3.09 (−5.60, −0.58) |
| MI, stroke, HHF, or all-cause mortality | 985 (29.74) | 970 (32.33) | 0.92 (0.84, 1.002) | −2.59 (−5.35, 0.16) |
Data are N events (incidence rate/1,000 person-years) unless otherwise indicated. MI, myocardial infarction; PY, person-years.
*
Hospitalization for myocardial infarction, ischemic or hemorrhagic stroke, or cardiovascular mortality.
†
Hospitalization for myocardial infarction, ischemic or hemorrhagic stroke, cardiovascular mortality, or HHF.